Abstracts tagged "quality of care and registry"

Abstract Number: 2985 • 2016 ACR/ARHP Annual Meeting
Practice-Level Variation in Quality of Care in the Acr’s Rheumatology Informatics System for Effectiveness (RISE) Registry
Jinoos Yazdany¹, Nick Bansback², Megan E. B. Clowse³, Deborah Collier⁴, Karen Law⁵, Katherine Liao⁶, Kaleb Michaud⁷, Esi Morgan⁸, Jim Oates⁹, Catalina Orozco¹⁰, Andreas Reimold¹¹, Julia F Simard¹², Rachel Myslinski¹³, Tracy Johansson¹⁴ and Salahuddin Kazi¹⁵, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ³Rheumatology, Duke University School of Medicine, Durham, NC, ⁴Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Internal Medicine, Emory University School of Medicine, Atlanta, GA, ⁶Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ¹⁰Rheumatology Associates, Dallas, TX, ¹¹Hospital of Southern Norway, Kristiansand, Norway, ¹²Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ¹³Governance & Ethics Specialist, Amer College of Rheumatology, Atlanta, GA, ¹⁴Practice, Advocacy & Quality, American College of Rheumatology, Atlanta, GA, ¹⁵Rheumatology, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: The Medicare Access and CHIP Reauthorization Act (MACRA) of 2015 has put into place an aggressive timeline for a Merit-Based Incentive Payment System (MIPS)…
Abstract Number: 1027 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Disease Activity Assessment Frequencies in Clinical Practices Do Not Support Treat-to-Target Care
David Sikes¹, James Bower², Drew Johnson³, J. Timothy Harrington², Rafia Khalil⁴, Edmund LaCour⁵, Michael Naarendorp⁶, Hillary Norton⁷ and Kathleen Thomas⁸, ¹Rheumatology, Florida Medical Clinic PA, Zephyrhills, FL, ²Joiner Associates LLC, Madison, WI, ³Crescendo Bioscience, Inc., South San Francisco, CA, ⁴Rafia Khalil Arthritis & Rheumatology Center, PC, Port Huron, MI, ⁵Dothan Medical Associates PC, Dothan, AL, ⁶Harlem Rhematology, LLC, New York, NY, ⁷Rheumatology, Santa Fe Rheumatology, Santa Fe, NM, ⁸Community Rheumatology, Noblesville, IN
Background/Purpose: Treat-to-Target (T2T) recommendations for rheumatoid arthritis (RA) care include standardized frequencies of disease activity (DA) assessment based on DA level. For this study, "on…
Abstract Number: 2317 • 2015 ACR/ARHP Annual Meeting
Different Rheumatoid Arthritis Disease Activity Measures Often Provide Discordant Results in Clinical Practice Populations
Gary Crump¹, James Bower², Terrence Foley³, J. Timothy Harrington², Nikita Hegde⁴, Drew Johnson⁵, Rafia Khalil⁶, Edmund LaCour⁷ and Robert Perhala⁸, ¹Rheumatology Associates - Louisville, Louisville, KY, ²Joiner Associates LLC, Madison, WI, ³Terrence Foley MD Inc, Concord Twp, OH, ⁴Akron General Hospital, Cuyahoga Falls, OH, ⁵Crescendo Bioscience, Inc., South San Francisco, CA, ⁶Rafia Khalil Arthritis & Rheumatology Center, PC, Port Huron, MI, ⁷Dothan Medical Associates PC, Dothan, AL, ⁸University Hospitals, Cleveland, OH
Background/Purpose: Accurate rheumatoid arthritis (RA) disease activity assessment is required for treatment consistent with Treat-to-Target (T2T) recommendations. Rheumatologists currently use a variety of patient-generated, physician-generated,…
Abstract Number: 2487 • 2015 ACR/ARHP Annual Meeting
Clinical Practices Participating in a Quality Improvement Project Make Progress in Implementing Population Management
Erin Arnold¹, William Arnold¹, James Bower², Douglas Conaway³, J. Timothy Harrington², Drew Johnson⁴, James Mossell⁵, Joy Schechtman⁶ and Anne Winkler⁷, ¹Orthopedics and Rheumatology of the North Shore, Skokie, IL, ²Joiner Associates LLC, Madison, WI, ³Rheumatology/Medicine, Carolina Health Specialists, Myrtle Beach, SC, ⁴Crescendo Bioscience, Inc., South San Francisco, CA, ⁵Arthritis and Osteo Center of South Georgia, Tifton, GA, ⁶Sun Valley Arthritis Center LTD, Peoria, AZ, ⁷Rheumatology, Winkler Medical Practice LLC, Springfield, MO
Background/Purpose: Population management (PM) offers a promising approach to providing Treat-to-Target (T2T) care for rheumatoid arthritis (RA). PM depends on providing standardized, on-time disease activity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].